Abbott (NYSE:ABT) announced today that it received expanded reimbursement coverage in Japan for the FreeStyle Libre system. Japan’s Ministry of Health, Labour and Welfare approved the expansion for the continuous glucose monitoring (CGM) system to include all people with diabetes who use insulin at least once per day. Abbott Park, Illinois-based Abbott said the expanded […]
abbott
Diabetes tech is off to a hot start in 2022
Diabetes tech developers have high hopes for the year ahead, some of which have already come to fruition. Change is continuous in continuous glucose monitoring (GCM), with expanded wear-times, improved accuracy and more. Meanwhile, never-ending innovation in insulin delivery is delivering wearable patches and closedloop delivery systems, making insulin management easier for people with diabetes. […]
How Bigfoot Biomedical plans to take diabetes management forward
For close to 20 years, Jeffrey Brewer has focused on finding ways to support insulin delivery and manage diabetes. Initially an entrepreneur, Brewer got involved with the Juvenile Diabetes Research Foundation (JDRF) and the Artificial Pancreas Project for developing a closed-loop insulin delivery system after his son was diagnosed with type 1 diabetes. After spending […]
Abbott CEO touts future of biowearables in first-ever healthcare company keynote at CES
Abbott (NYSE:ABT) Chairman & CEO Robert B. Ford highlighted what the future holds as he presented the first healthcare keynote ever at CES. Abbott Park, Illinois-based Abbott is designing biowearables based on its Freestyle Libre platform, with sensor technology designed to track key signals in the body like glucose, ketones and lactate, and could even one […]
12 of medtech’s biggest personnel changes in 2021
As medtech companies continued to drive innovation throughout the past 12 months, a number of high-level executives led the way. Some of those companies and those executives opted for major changes over the course of 2021, though, with some high-profile moves from medtech giant to medtech giant. Here are some of the biggest personnel moves […]
How some diabetes tech companies are honoring National Diabetes Month
World Diabetes Day (Nov. 14) may have passed, but it remains National Diabetes Month through the end of November. A number of companies developing some of the most intriguing innovations in diabetes care have also stepped forward this month to organize awareness-raising efforts for the metabolic disease. Here are some steps a handful of diabetes […]
FreeStyle Libre 3, other Abbott products recognized at CES Innovation Awards
Abbott (NYSE:ABT) was honored for a handful of its offerings at the Consumer Electronics Show (CES) 2022 Innovation Awards. The company’s FreeStyle Libre 3 continuous glucose monitoring (CGM) system ranked among the top 15 products in the CES “Best of Innovation” category. The next-generation CGM system features the world’s smallest, thinnest glucose sensor that can be […]
Abbott, American Diabetes Association partner to help people of color with diabetes
Abbott (NYSE:ABT) and the American Diabetes Association (ADA) announced today that they launched a joint community health partnership in Ohio. The community initiative — the first under the ADA’s Health Equity Now platform — will launch in Columbus, Ohio, and be conducted with the National Center for Urban Solutions (NCUS) in an effort to better […]
FDA clears Abbott’s iPhone app for FreeStyle Libre 2
Abbott (NYSE:ABT) announced today that it received FDA clearance for its FreeStyle Libre 2 iOS application for use with compatible iPhones. The Abbott Park, Ill.-based company designed the new FreeStyle Libre 2 app to enable users to get glucose readings directly on their iPhones without the use of a reader, allowing caregivers to remotely monitor […]
Abbott CMO Dr. Nick West touts latest iteration of drug-eluting stent
Abbott executive Dr. Nick West believes the company offers the “best-in-class” drug-eluting stent with its Xience platform. When Abbott (NYSE:ABT) CMO & divisional VP of global medical affairs for its vascular business Dr. Nick West looks back at his use of drug-eluting stents in the early 2000s, all he sees now is innovation. As a practicing interventional cardiologist, West […]